Fair Value Calculator Fair Value Calculator
EN DE

Zimmer Biomet Holdings (Z1BH34) Fair Value & Analysis

Healthcare · BR · Market cap R$86.4B

ZB Zimmer Biomet Holdings Z1BH34 · SA
PriceR$111.66
Fair ValueR$16.59
Upside-85.1%
Quality58/100
Watch Zimmer Biomet Holdings for free, get notified when fair value or trend changes. Watch for free
Evidence: High Range R$11.10 – R$22.78 📤 Share as image

Fair value as of: Jul 18, 2026

From 26 valuation models · updated 4 days ago

Fair value updated Jul 18, 2026, revised from R$17.42 to R$16.59 (−4.8%) since Jun 24, 2026. Share price −3.7% over the past month.

Price vs Fair Value (12 months)

R$128.37 R$111.45 Fair Value R$16.59 Jul 2025 Jul 2026

12‑month range R$111.45 – R$128.37 · fair‑value band R$11.10 – R$22.78 · the R$111.66 price screens above the R$16.59 fair value. As of Jul 18, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Zimmer Biomet Holdings (Z1BH34) currently trades at R$111.66, while our model-based Fair Value estimate is R$16.59, implying the stock looks roughly 85.1% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Zimmer Biomet Holdings generated revenue of R$8.4B at a net margin of 9.1%. Revenue grew 9.3% year over year. It earns a return on equity of 6.1%. Net debt stands at R$6.9B. Fundamentals as of Jul 18, 2026

Our scenario range runs from R$11.10 (bear case) to R$22.78 (bull case); at R$111.66, the current price sits above that range. The share trades about 13% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -85%, Z1BH34 screens richer than that median.

Key figures & financial health

Revenue (TTM) R$8.4B
Revenue growth (YoY) +9.3%
Net margin 9.1%
Return on equity 6.1%
Free cash flow R$1.4B FY2025
P/E ratio 24.5
More key figures
Operating margin 19.7%
EPS (TTM) R$4.89
Dividend yield 0.8%
EPS growth (YoY) +34.1%
Net debt R$6.9B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.

About the company

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders …

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Zimmer Biomet Holdings reported revenue of R$8.2B in FY2025 versus R$6.8B in FY2021, a compound +4.8%/yr. Reported net income was R$705M in FY2025, compounding +15.1%/yr from FY2021.

Revenue +4.8%/yr
FY21 R$6.8B
FY22 R$6.9B
FY23 R$7.4B
FY24 R$7.7B
FY25 R$8.2B
Net income +15.1%/yr
FY21 R$402M
FY22 R$231M
FY23 R$1.0B
FY24 R$904M
FY25 R$705M

Is Z1BH34 fairly valued? → Check now

📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog, it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Zimmer Biomet Holdings Fair Value". https://www.fairvalue-calculator.com/stock/Z1BH34

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $89.17 $70.59 -21%
Stryker Corporation SYK $308.84 $187.83 -39%
Medtronic plc MDTC34 R$213.40 R$31.21 -85%
Boston Scientific Corporation B1SX34 R$229.30 R$43.33 -81%
Edwards Lifesciences Corporation EWL €74.82 €32.56 -56%
Siemens Healthineers AG SEMHF $39.95 $44.36 +11%
DexCom, Inc DXCM $69.07 $65.56 -5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥144.39 ¥105.08 -27%
STERIS plc S1TE34 R$52.14 R$39.50 -24%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Zimmer Biomet Holdings (Z1BH34) undervalued?
As of Jul 18, 2026, our model estimates a fair value of R$16.59 versus a price of R$111.66, about −85% (overvalued). Model-based estimate, not financial advice.
What is the fair value of Z1BH34?
Our model-based fair value for Zimmer Biomet Holdings is R$16.59 (as of Jul 18, 2026), built from audited fundamentals. The current price is R$111.66.
What is the quality score of Z1BH34?
Zimmer Biomet Holdings has a Quality Score of 58/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Zimmer Biomet Holdings (Z1BH34)?
Zimmer Biomet Holdings reported trailing-twelve-month revenue of about R$8.4B (latest available figure, as of Jul 18, 2026).
What is the net profit margin of Z1BH34?
The net profit margin of Zimmer Biomet Holdings is about 9.1%, meaning it keeps roughly 9.1% of revenue as net income. Based on the latest reported figures.
Does Zimmer Biomet Holdings pay a dividend?
Zimmer Biomet Holdings currently shows a dividend yield of about 0.80% relative to its recent price (as of Jul 18, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Unlock the full Zimmer Biomet Holdings analysis, and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.